Clik here to view.
Jim Cramer: Buy Best Buy, Bristol-Myers Squibb, and These 2 Stocks
Jim Cramer made the following calls on October 29th, 2013. What do you think about his picks? Best Buy Co. Inc. (NYSE:BBY): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy...
View ArticleClik here to view.
Analysts: GE Can Meet or Beat 2013 Expectations and 3 More Research Notes to...
General Electric Co. (NYSE:GE): UBS believes that General Electric’s risk/reward profile is favorable through the end of the year and is on track to meet or even beat its fiscal year 2013 expectations....
View ArticleClik here to view.
4 Healthcare Stock Stories for Midweek Investment Wellness
GlaxoSmithKline Plc (NYSE:GSK): Closing price $53.32 Drug makers GlaxoSmithKline and Lupin Ltd. are among others who must deal with Indian distributors, whose insistence upon maintaining commissions...
View ArticleClik here to view.
4 Mergers and Acquisitions Stock Stories for a Savvy Friday Read
Alcatel-Lucent SA (NYSE:ALU): Current price $4.07 Sources told Reuters that Alcatel-Lucent is exploring the sale ohttp://wallstcheatsheet.com/wp-admin/post.php?post=562117&action=editf a unit that...
View ArticleClik here to view.
Merck’s New Cancer Drug Boosts Its Rating
Merck & Co., Inc.’s (NYSE:MRK) shares are at a 52-week high on Monday after a recent upgrade to the company’s shares, even as the majority of the market is sluggish at the start of the new year,...
View ArticleClik here to view.
Bristol-Myers and Pfizer Win Approval of New Indication for Eliquis
Bristol-Myers Squibb & Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. The drug is now...
View ArticleClik here to view.
Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?
Source: Thinkstock The race for a hepatitis C cure is closing in fast; Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) both announced Thursday that clinical trials of their...
View ArticleClik here to view.
6 Drugs That Could Move the Pharma Market
Overview In the last few years, a number of promising drugs that treat serious conditions and diseases have come through drugmakers’ pipelines. Recent developments in oncology, for instance, mean that...
View ArticleClik here to view.
The Top 5 Biggest Pharma Deals of 2013
5. AstraZeneca/Bristol-Myers Squibb Co. AstraZeneca Group Plc (NYSE:AZN) and Bristol-Myers Squibb Co. (NYSE:BMY) had been in a long-term partnership for six years before Bristol-Myers Squibb decided...
View ArticleClik here to view.
Which of These 10 Best Selling Cancer Drugs Are Here to Stay?
Source: Thinkstock If you look at the pharmaceutical industry’s most promising investigational drugs (which you can do right here), cancer therapies comprise the vast majority of the industry’s recent...
View ArticleClik here to view.
Jim Cramer: Buy Best Buy, Bristol-Myers Squibb, and These 2 Stocks
Jim Cramer made the following calls on October 29th, 2013. What do you think about his picks? Best Buy Co. Inc. (NYSE:BBY): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy...
View ArticleClik here to view.
Analysts: GE Can Meet or Beat 2013 Expectations and 3 More Research Notes to...
General Electric Co. (NYSE:GE): UBS believes that General Electric’s risk/reward profile is favorable through the end of the year and is on track to meet or even beat its fiscal year 2013 expectations....
View ArticleClik here to view.
4 Healthcare Stock Stories for Midweek Investment Wellness
GlaxoSmithKline Plc (NYSE:GSK): Closing price $53.32 Drug makers GlaxoSmithKline and Lupin Ltd. are among others who must deal with Indian distributors, whose insistence upon maintaining commissions...
View ArticleClik here to view.
4 Mergers and Acquisitions Stock Stories for a Savvy Friday Read
Alcatel-Lucent SA (NYSE:ALU): Current price $4.07 Sources told Reuters that Alcatel-Lucent is exploring the sale ohttps://www.cheatsheet.com/wp-admin/post.php?post=562117&action=editf a unit that...
View ArticleClik here to view.
Merck’s New Cancer Drug Boosts Its Rating
Merck & Co., Inc.’s (NYSE:MRK) shares are at a 52-week high on Monday after a recent upgrade to the company’s shares, even as the majority of the market is sluggish at the start of the new year,...
View ArticleClik here to view.
Bristol-Myers and Pfizer Win Approval of New Indication for Eliquis
Bristol-Myers Squibb & Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. The drug is now...
View ArticleClik here to view.
Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?
Source: Thinkstock The race for a hepatitis C cure is closing in fast; Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) both announced Thursday that clinical trials of their...
View ArticleClik here to view.
6 Drugs That Could Move the Pharma Market
Overview In the last few years, a number of promising drugs that treat serious conditions and diseases have come through drugmakers’ pipelines. Recent developments in oncology, for instance, mean that...
View ArticleClik here to view.
The Top 5 Biggest Pharma Deals of 2013
5. AstraZeneca/Bristol-Myers Squibb Co. AstraZeneca Group Plc (NYSE:AZN) and Bristol-Myers Squibb Co. (NYSE:BMY) had been in a long-term partnership for six years before Bristol-Myers Squibb decided...
View ArticleClik here to view.
Which of These 10 Best Selling Cancer Drugs Are Here to Stay?
Source: Thinkstock If you look at the pharmaceutical industry’s most promising investigational drugs (which you can do right here), cancer therapies comprise the vast majority of the industry’s recent...
View Article